Radiolabeled GPVI-Fc for PET Imaging of Multiple Extracellular Matrix Fibers: A New Look into Pulmonary Fibrosis Progression
暂无分享,去创建一个
M. Schaller | L. Quintanilla‐Martinez | G. Reischl | B. Pichler | N. Beziere | I. González-Menéndez | A. Maurer | M. Gawaz | Simon Isser
[1] M. Salvatore,et al. The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease , 2022, Frontiers in Medicine.
[2] J. Finnerty,et al. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis , 2021, BMC Pulmonary Medicine.
[3] Ying Zhou,et al. Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases , 2021, Frontiers in Pharmacology.
[4] H. Kauczor,et al. Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study , 2021, The Journal of Nuclear Medicine.
[5] J. Waterton,et al. Imaging Biomarkers in Animal Models of Drug-Induced Lung Injury: A Systematic Review , 2020, Journal of clinical medicine.
[6] L. Olsson,et al. Longitudinal Imaging Using PET/CT with Collagen-I PET-Tracer and MRI for Assessment of Fibrotic and Inflammatory Lesions in a Rat Lung Injury Model , 2020, Journal of clinical medicine.
[7] F. Fraioli,et al. Synergistic application of pulmonary 18F-FDG PET/HRCT and computer-based CT analysis with conventional severity measures to refine current risk stratification in idiopathic pulmonary fibrosis (IPF) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[8] M. Gawaz,et al. Imaging fibrosis in inflammatory diseases: targeting the exposed extracellular matrix , 2019, Theranostics.
[9] P. Caravan,et al. Molecular Probes for Imaging Fibrosis and Fibrogenesis. , 2018, Chemistry.
[10] Jong Sun Park,et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.
[11] S. Goldman,et al. Assessment of 18F-FDG uptake in idiopathic pulmonary fibrosis: influence of lung density changes , 2018, European Journal of Hybrid Imaging.
[12] S. Goldman,et al. Absence of early metabolic response assessed by 18F-FDG PET-CT after initiation of antifibrotic drugs in IPF patients. , 2018, Idiopathic interstitial pneumonias.
[13] Thomas Lindner,et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.
[14] S. Watson,et al. Immobilized fibrinogen activates human platelets through glycoprotein VI , 2018, Haematologica.
[15] E. Warburton,et al. Platelet collagen receptor Glycoprotein VI‐dimer recognizes fibrinogen and fibrin through their D‐domains, contributing to platelet adhesion and activation during thrombus formation , 2018, Journal of thrombosis and haemostasis : JTH.
[16] C. Henke,et al. Extracellular matrix as a driver of progressive fibrosis. , 2018, The Journal of clinical investigation.
[17] Martine,et al. Immobilized fibrinogen activates human platelets through glycoprotein , 2018 .
[18] Y. Hagihara,et al. Heat denaturation of the antibody, a multi-domain protein , 2017, Biophysical Reviews.
[19] G. Raghu. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years , 2017, European Respiratory Journal.
[20] V. Aidinis,et al. Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis , 2017, Front. Med..
[21] M. Mino‐Kenudson,et al. Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models , 2017, Science Translational Medicine.
[22] Christos Lionis,et al. Early diagnosis of IPF: time for a primary-care case-finding initiative? , 2014, The Lancet. Respiratory medicine.
[23] S. Rosselot. Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[24] E. Nagel,et al. Positron Emission Tomography/Computed Tomographic and Magnetic Resonance Imaging in a Murine Model of Progressive Atherosclerosis Using 64Cu-Labeled Glycoprotein VI-Fc , 2013, Circulation. Cardiovascular imaging.
[25] A. Chiribiri,et al. Ex vivoimaging of injured arteries in rabbits using fluorescence-labelled glycoprotein VI-Fc , 2012, Platelets.
[26] V. Aidinis,et al. Modeling pulmonary fibrosis with bleomycin , 2011, Current opinion in pulmonary medicine.
[27] M. Gawaz,et al. Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans , 2011, Circulation.
[28] S. Kleeberger,et al. Mouse Models of Bleomycin‐Induced Pulmonary Fibrosis , 2008, Current protocols in pharmacology.
[29] C. Hogaboam,et al. Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[30] M. Moroi,et al. Platelet glycoprotein VI. , 2008, Advances in experimental medicine and biology.
[31] M. Moroi,et al. Platelet glycoprotein VI: its structure and function. , 2004, Thrombosis research.
[32] Y. Liu,et al. The Platelet Receptor GPVI Mediates Both Adhesion and Signaling Responses to Collagen in a Receptor Density-dependent Fashion* , 2002, The Journal of Biological Chemistry.